| Autor: |
Peters, Remco P H, Klausner, Jeffrey D, Mazzola, Laura, Mdingi, Mandisa M, Jung, Hyunsul, Gigi, Ranjana M S, Piton, Jeremie, Daniels, Joseph, de Vos, Lindsey, Adamson, Paul C, Gleeson, Birgitta, Ferreyra, Cecilia |
| Zdroj: |
The Lancet; February 2024, Vol. 403 Issue: 10427 p657-664, 8p |
| Abstrakt: |
A rapid and affordable point-of-care test is a priority for Neisseria gonorrhoeaecontrol. WHO and Foundation for Innovative New Diagnostics (FIND) have a target product profile for a non-molecular N gonorrhoeaerapid point-of-care test that requires a clinical sensitivity of greater than 80% and a specificity over 95% to be considered useful in syndromic management; test turnaround time should be 30 min or under, and the test should cost less than US$3. A novel lateral flow assay (LFA) was developed to achieve that profile. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
